26 articles with Medicenna
Strong interim survival trend (15.2 vs 8.5 months) emerging in IL4R positive patients
Medicenna Shows Promising Pre-Clinical Results in Solid Tumor Models with its IL-2 Superkine, MDNA109
Magnified IL-2 affinity towards CD122 potently synergizes with checkpoint inhibitors
Medicenna Therapeutics Corp. announced today that it has received US$1,224,540 (approximately, CD$1.6M) from the Cancer Prevention and Research Institute of Texas ("CPRIT").
Medicenna Therapeutics Corp. will be presenting an update on previously announced data from the Company's MDNA109 and MDNA55 programs at the following conferences:
Medicenna Therapeutics Corp. today announced promising interim efficacy and safety results from patients treated at low doses in the on-going Phase 2b clinical trial of MDNA55.
Medicenna Presented Insights from the Phase 2b Clinical Trial of MDNA55 at the European Society for Medical Oncology 2018 Congress
Dr. Martin Bexon, Head of Clinical Development at Medicenna, presented results outlining the patterns of responses seen in the MDNA55 Phase 2b clinical trial in patients treated at low doses implemented during the first half of the study.
The MDNA55 Phase 2b clinical trial is for the treatment of recurrent glioblastoma
Announces Notice of Allowance of US Patent for IL-2 Superkine Agonists and Antagonist
Promising Pre-Clinical Efficacy, Safety and Pharmacokinetics Shown by Long-Acting Fusions of MDNA109
Medicenna Therapeutics Corp. announced that the United States Patent and Trademark Office issued a Notice of Allowance related to the Company's MDNA57 program.
Medicenna Amends Protocol of Phase 2b Recurrent Glioblastoma Study of MDNA55 in Response to Strong Safety Data and Early Efficacy Read-outs
Medicenna Therapeutics Corp. announced that half the patients in the ongoing Phase 2b study of MDNA55 in recurrent glioblastoma (rGBM) have been recruited and the data to date demonstrate solid safety results and early signals of efficacy based on the findings of the Safety Review and Clinical Advisory Committees, comprised of key opinion leaders and study investigators.
Medicenna today reported financial results for the three and nine months ended December 31, 2017.
Medicenna Presents Updates on Phase IIb Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology
MDNA55, is the Company's lead immunotherapeutic agent targeting the interleukin-4 receptor which is known to be over-expressed in brain tumors and the tumor micro-environment but not in healthy brain tissue.
The poster presentation by Dr. Bexon provides an overview of the safety and efficacy results from previous Phase I and II clinical trials of the targeted immunotherapy, MDNA55, in 66 patients with recurrent glioblastoma, the most common and deadly form of brain cancer.
Medicenna today reported financial results for the three and six months ended September 30, 2017.
Medicenna today announced that the U.S. Patent and Trademark Office issued another patent related to the Company's Superkine platform. U.S. Patent 9,738,696.
Medicenna is pleased to announce that the Company has received approval to commence trading on the OTCQX Best Market, under the symbol, "MDNAF".